Lv6
2660 积分 2022-02-25 加入
Four-Year Outcomes of First-Line Nivolumab Plus Ipilimumab for 6 Months Versus Continuation in Patients With Advanced NSCLC: Results of the Randomized IFCT-1701 “DICIPLE” Phase III Trial
2天前
已完结
Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis
18天前
已完结
Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy
18天前
已完结
Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer
1个月前
已完结
Current Roles of Neoadjuvant and Perioperative Immunotherapy in Non-Small Cell Lung Cancer
1个月前
已关闭
First-line Pembrolizumab Plus Lenvatinib for Advanced Non–clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial
4个月前
已完结
Perioperative Apalutamide in High-Risk Localized Prostate Cancer
4个月前
已完结
NSCLC: Five trials to watch
5个月前
已关闭
Radiotherapy for more efficacious novel anticancer drugs: a position paper from the European Society for Radiotherapy and Oncology (ESTRO) focus group on novel systemic therapies and radiotherapy
5个月前
已完结
Targeting Androgen Receptor Mutations in Metastatic Castration-Resistant Prostate Cancer with a Novel Androgen Biosynthesis Inhibitor
5个月前
已完结
皖公网安备34019202002308
